DK2593797T3 - Hidtil ukendte fremgangsmåder til proteinevolution - Google Patents

Hidtil ukendte fremgangsmåder til proteinevolution Download PDF

Info

Publication number
DK2593797T3
DK2593797T3 DK11807192.7T DK11807192T DK2593797T3 DK 2593797 T3 DK2593797 T3 DK 2593797T3 DK 11807192 T DK11807192 T DK 11807192T DK 2593797 T3 DK2593797 T3 DK 2593797T3
Authority
DK
Denmark
Prior art keywords
protein evolution
unknown
procedures
unknown procedures
evolution
Prior art date
Application number
DK11807192.7T
Other languages
English (en)
Inventor
Jay M Short
Original Assignee
Bioatla Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Llc filed Critical Bioatla Llc
Application granted granted Critical
Publication of DK2593797T3 publication Critical patent/DK2593797T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Ecology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK11807192.7T 2010-07-16 2011-03-04 Hidtil ukendte fremgangsmåder til proteinevolution DK2593797T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36521610P 2010-07-16 2010-07-16
PCT/US2011/027252 WO2012009026A2 (en) 2010-07-16 2011-03-04 Novel methods of protein evolution

Publications (1)

Publication Number Publication Date
DK2593797T3 true DK2593797T3 (da) 2019-08-05

Family

ID=45469988

Family Applications (2)

Application Number Title Priority Date Filing Date
DK11807192.7T DK2593797T3 (da) 2010-07-16 2011-03-04 Hidtil ukendte fremgangsmåder til proteinevolution
DK18194688.0T DK3435087T3 (da) 2010-07-16 2011-03-04 Hidtil ukendte fremgangsmåder til proteinevolution

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK18194688.0T DK3435087T3 (da) 2010-07-16 2011-03-04 Hidtil ukendte fremgangsmåder til proteinevolution

Country Status (9)

Country Link
US (3) US10106576B2 (da)
EP (2) EP2593797B1 (da)
CN (2) CN103003696B (da)
AU (1) AU2011279747B2 (da)
CA (1) CA2804746C (da)
DK (2) DK2593797T3 (da)
ES (2) ES2966088T3 (da)
SG (2) SG187033A1 (da)
WO (1) WO2012009026A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3553089A1 (en) 2012-05-10 2019-10-16 Bioatla, LLC Multi-specific monoclonal antibodies
ES2819865T3 (es) * 2014-01-07 2021-04-19 Bioatla Llc Proteínas dirigidas a ortólogos
CN109696550B (zh) * 2017-10-20 2022-08-26 成都蓝瑙生物技术有限公司 用于脑中风的发光elisa体液样品稳定化用水溶液
CN112513081A (zh) 2018-06-14 2021-03-16 生物蛋白有限公司 多重特异性抗体构建体
JP7720785B2 (ja) 2019-04-18 2025-08-08 ブリストル-マイヤーズ スクイブ カンパニー 低pHで結合するために特異性が増強されたイピリムマブバリアント
EP3966227A1 (en) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
WO2023023055A1 (en) 2021-08-16 2023-02-23 Renagade Therapeutics Management Inc. Compositions and methods for optimizing tropism of delivery systems for rna
TW202328067A (zh) 2021-09-14 2023-07-16 美商雷納嘉德醫療管理公司 環狀脂質及其使用方法
WO2023044343A1 (en) 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Acyclic lipids and methods of use thereof
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023122752A1 (en) 2021-12-23 2023-06-29 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
CA3255619A1 (en) 2022-04-07 2023-10-12 Renagade Therapeutics Management Inc. CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
CA3263767A1 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. COMPOSITIONS AND PROCESSES ALLOWING CROSSING THE BLOOD-BRAIN BARRIER
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2026102093A1 (en) 2024-11-07 2026-05-15 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
EP0359789B1 (en) 1988-01-21 1993-08-04 Genentech, Inc. Amplification and detection of nucleic acid sequences
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム インターナショナル,インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
DK0672145T3 (da) 1992-11-24 2003-08-11 Searle & Co Interleukin-3-(IL-3)-polypeptider med flere mutationer
EP0866853B1 (en) * 1995-12-07 2004-03-03 Diversa Corporation Method of screening for enzyme activity
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US20030219752A1 (en) * 1995-12-07 2003-11-27 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US7033781B1 (en) 1999-09-29 2006-04-25 Diversa Corporation Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
PL362324A1 (en) 2001-02-19 2004-10-18 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
JP2004532038A (ja) * 2001-05-17 2004-10-21 ディヴァーサ コーポレイション 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
AU2006304387A1 (en) 2005-10-14 2007-04-26 Medimmune, Llc Cell display of antibody libraries
US20090309617A1 (en) 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
WO2009059235A2 (en) 2007-11-01 2009-05-07 Facet Biotech Corporation Immunoglobulin display vectors
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
SG10201700096VA (en) * 2009-07-17 2017-02-27 Bioatla Llc Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts
WO2011109726A2 (en) * 2010-03-05 2011-09-09 Bioatla Llc Homologous multi-specific antibodies
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives

Also Published As

Publication number Publication date
US20130116125A1 (en) 2013-05-09
CA2804746A1 (en) 2012-01-19
US10106576B2 (en) 2018-10-23
WO2012009026A3 (en) 2012-09-07
ES2741175T3 (es) 2020-02-10
ES2966088T3 (es) 2024-04-18
US20210017221A1 (en) 2021-01-21
CN105924499A (zh) 2016-09-07
WO2012009026A2 (en) 2012-01-19
EP3435087A1 (en) 2019-01-30
EP3435087B1 (en) 2023-11-08
US20180362576A1 (en) 2018-12-20
AU2011279747B2 (en) 2015-07-16
CA2804746C (en) 2022-01-11
CN105924499B (zh) 2020-09-15
SG187033A1 (en) 2013-02-28
CN103003696A (zh) 2013-03-27
US10829513B2 (en) 2020-11-10
US11639365B2 (en) 2023-05-02
EP2593797A2 (en) 2013-05-22
CN103003696B (zh) 2016-06-01
SG10201902596TA (en) 2019-04-29
EP2593797A4 (en) 2014-01-08
EP2593797B1 (en) 2019-05-08
DK3435087T3 (da) 2023-11-27
AU2011279747A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
DK3435087T3 (da) Hidtil ukendte fremgangsmåder til proteinevolution
DK2606061T3 (da) Bindingsproteiner til hepcidin
DK3053932T3 (da) Hidtil ukendte ctla4-ig-immunoadhesiner
SI3703369T1 (sl) Združevanje območij vzorcev
CO6950481A2 (es) Inhibidores de proteínas quinasas
DK2536830T3 (da) Polypeptider
EP2406399A4 (en) MIRAC PROTEINS
DK2443154T3 (da) Bispecifikke antigenbindingsproteiner
PL3415531T3 (pl) Białka wiążące antygen
IL225897A0 (en) Cxcr2 binding polypeptides
IL226307A0 (en) Compounds and methods for treating pain
DK2625295T3 (da) High-throughput-immunsekvensering
DK3459564T3 (da) Plasmakallikreinbindende proteiner
PL3299380T3 (pl) Sposoby oczyszczania polipeptydów
DK3275896T3 (da) Fremgangsmåde til at opnå antistoffer
DK2598514T3 (da) Proteinoprensning
BR112013012217A2 (pt) incubadora
DK2654736T3 (da) Hidtil ukendt farmaceutisk sammensætning
ME02224B (me) Antikancerski fuzioni protein
CO6791565A2 (es) Anticuerpos anti-notch1
DK2564396T3 (da) Fremgangsmåde til isotop-fremstilling
BR112013008347A2 (pt) polipeptídeos de variantes cbh i
DK2618842T3 (da) Hidtil ukendt immunstimulerende fremgangsmåde
EP2558859A4 (en) MICRO ARRAYS
EP2592033A4 (en) Elevator rope